Industry

MARLBOROUGH, Mass.–(BUSINESS WIRE)–$HOLX #CourtofAppeals–Hologic, Inc. (Nasdaq: HOLX) announced today that the U.S. Court of Appeals for the Federal Circuit has affirmed a 2018 district court ruling that barred Minerva from challenging the validity of the patent rights it assigned to Hologic. “We are pleased that the U.S. Court of Appeals has once again ruled in … [Read more…]

Not for distribution to U.S. news wire services or for dissemination in the U.S. TORONTO–(BUSINESS WIRE)–LifeWorks Inc. (the “Company” or “LifeWorks”) (TSX: LWRK) today reported its financial results for the three and six-month period ended June 30, 2022 (all amounts are in Canadian dollars, unless noted otherwise). LifeWorks acquisition by TELUS Binding agreement for C$2.9 … [Read more…]

Not for distribution to U.S. news wire services or for dissemination in the U.S. VANCOUVER, British Columbia & TORONTO–(BUSINESS WIRE)–TELUS Corporation (“TELUS”) (TSX: T; NYSE: TU) and LifeWorks Inc. (“LifeWorks”) (TSX: LWRK) today announced that the Ontario Superior Court of Justice (Commercial List) has granted its final order (the “Court Approval”) approving the plan of … [Read more…]

MELVILLE, N.Y.–(BUSINESS WIRE)–Henry Schein, Inc. (Nasdaq: HSIC) announced the passing today of E. Dianne Rekow, DDS, Ph.D., a member of the Company’s Board of Directors since 2014 and a leader in the development of digital dentistry. “Dianne was an extraordinary board member and an internationally known authority on aesthetic and restorative dentistry as well as … [Read more…]

Evaluation of PALISADE-1 continues and interim analysis of PALISADE-2 begins Preliminary data from nearly 200 subjects in the PALISADE open label safety study suggest that continued as-needed use of PH94B has potential to achieve cumulative functional improvement in the severity of social anxiety disorder (SAD) SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–$VTGN #mentalhealth—VistaGen Therapeutics, Inc. (Nasdaq: VTGN), … [Read more…]

Corporate restructuring underway and MASTERS-2 clinical trial prioritized Conference call begins at 4:30 p.m. Eastern time today CLEVELAND–(BUSINESS WIRE)–$ATHX #ARDS–Athersys, Inc. (NASDAQ: ATHX) announced today its financial results for the three and six months ended June 30, 2022 and provided a business update. Second quarter 2022 Corporate and Operational Highlights: Corporate Restructuring Implemented a restructuring … [Read more…]

On Track to Dose the First Patient in the Phase 1 Study Evaluating Belzupacap Sarotalocan (AU‑011) for the Treatment of Non-Muscle Invasive Bladder Cancer in Q3 2022 On Track to Initiate Pivotal Trial in Early-Stage Choroidal Melanoma in Q4 2022 BOSTON–(BUSINESS WIRE)–Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of … [Read more…]

Signs Supply Agreement and Receives First Commercial Purchase Order from Top-Tier Medtech Company for Bioptx™ Baseline Band, Targets Fourth Quarter to Begin Shipping Signs First Contract Research Organization Partnership to Develop and Evaluate Rockley’s Bioptx™ Biomarker Sensing Platform for Use in Clinical Trials Bolsters Board of Directors and Establishes Scientific Advisory Board OXFORD, England & … [Read more…]

— Full data support the potential of obicetrapib to address unmet medical need for millions of patients who cannot achieve their LDL-C targets with high-intensity statin therapy (HIS) alone — — Treatment with obicetrapib in patients on high-intensity statin therapy was observed to have statistically significant impact on LDL-C, as well as significant impacts on … [Read more…]

˗ ALBRIOZA™ (also known as AMX0035) now commercially available in Canada, representing first product launch for Amylyx ˗ FDA Advisory Committee meeting to review new drug application for AMX0035 for the treatment of ALS scheduled for September 7, 2022; assigned PDUFA action date of September 29, 2022; U.S. commercial team now launch ready ˗ Marketing … [Read more…]